XML 52 R36.htm IDEA: XBRL DOCUMENT
v3.26.1

Related Party Transactions (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2026
Related Party Transactions |
Schedule of common stock sold to related parties | As part of the registered direct offering, the following number of shares of common stock, pre-funded warrants and common warrants were sold to related parties:
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ ​ ​ | Number of | ​ | Number of | ​ ​ ​ | Number of | ​ | Aggregate
​ | ​ | ​ | Shares of | ​ | Pre-Funded | ​ | Common | ​ | Purchase
​ | ​ ​ ​ | Common Stock | ​ ​ ​ | Warrants | ​ ​ ​ | Warrants | ​ ​ ​ | Price
OrbiMed Advisors LLC (1) | ​ | ​ | — | ​ | ​ | 1,444,085 | ​ | ​ | 1,397,684 | ​ | $ | 2,499,856
Puissance Capital Management (2) | ​ | ​ | 866,451 | ​ | ​ | — | ​ | ​ | 838,610 | ​ | ​ | 1,500,000
Richard A. Miller, M.D. (3) | ​ | ​ | 577,634 | ​ | ​ | — | ​ | ​ | 559,073 | ​ | ​ | 1,000,000
William B. Jones, Ph.D. (4) | ​ | ​ | 20,001 | ​ | ​ | — | ​ | ​ | 19,357 | ​ | ​ | 34,624
| (1) | Peter Thompson, M.D., a member of the Company’s Board of Directors since November 2014, is a Private Equity Partner at OrbiMed Advisors, LLC.
| (2) | Ted Wang, Ph.D., a Co-Founder, General Manager and Director of Angel Pharmaceuticals, of which the Company holds a 49% ownership interest, is the founder of Puissance Capital Management.
| (3) | Richard A. Miller, M.D. is the Company’s President, Chief Executive Officer and Chairman of the Board of Directors.
| (4) | William B. Jones, Ph.D. is the Company’s Senior Vice President, Pharmaceutical Development.
​ During the three months ended June 30, 2025, all of the common warrants sold to related parties as part of the Company’s May 2024 registered direct offering were exercised. The details of these exercises are as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ ​ ​ | ​ | ​ | Number of | ​ | ​
​ | ​ | Number of | ​ | Common Shares | ​ | ​ | Aggregate
​ | ​ | Common Warrants | ​ | Issued Upon | ​ | Proceeds Received
​ | ​ ​ ​ | Exercised | ​ ​ ​ | Exercise | ​ ​ ​ | Upon Exercise
OrbiMed Advisors LLC (1) | ​ | ​ | 1,397,684 | ​ | ​ | 221,352 | ​ | $ | —
Puissance Capital Management | ​ | ​ | 838,610 | ​ | ​ | 838,610 | ​ | ​ | 2,935,135
Richard A. Miller, M.D. | ​ | ​ | 559,073 | ​ | ​ | 559,073 | ​ | ​ | 1,956,756
William B. Jones, Ph.D. | ​ | ​ | 19,357 | ​ | ​ | 19,357 | ​ | ​ | 67,750
| (1) | OrbiMed Advisors LLC paid the exercise price of $3.50 per common stock warrant on a cashless basis, resulting in the Company withholding 1,176,332 of the warrant shares to pay the exercise price and issuing to OrbiMed Advisors LLC the remaining 221,352 shares. This transaction is considered a non-cash financing activity.

X
- References No definition available. + Details
Name: | us-gaap_RelatedPartyTransactionsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details
Name: | us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration